55502-03-9Relevant academic research and scientific papers
Ratiometric Fluorescent Probe for Lysosomal pH Measurement and Imaging in Living Cells Using Single-Wavelength Excitation
Liu, Xingjiang,Su, Yuanan,Tian, Huihui,Yang, Lei,Zhang, Hongyan,Song, Xiangzhi,Foley, James W.
, p. 7038 - 7045 (2017)
A novel lysosome-targeting ratiometric fluorescent probe (CQ-Lyso) based on the chromenoquinoline chromorphore has been developed for the selective and sensitive detection of intracellular pH in living cells. In acidic media, the protonation of the quinol
Synthesis and Antileishmanial Evaluation of Arylimidamide-Azole Hybrids Containing a Phenoxyalkyl Linker
Abdelhameed, Ahmed,Feng, Mei,Joice, April C.,Zywot, Emilia M.,Jin, Yiru,La Rosa, Chris,Liao, Xiaoping,Meeds, Heidi L.,Kim, Yena,Li, Junan,McElroy, Craig A.,Wang, Michael Zhuo,Werbovetz, Karl A.
, p. 1901 - 1922 (2021/02/22)
Due to the limitations of existing medications, there is a critical need for new drugs to treat visceral leishmaniasis. Since arylimidamides and antifungal azoles both show oral activity in murine visceral leishmaniasis models, a molecular hybridization approach was employed where arylimidamide and azole groups were separated by phenoxyalkyl linkers in an attempt to capitalize on the favorable antileishmanial properties of both series. Among the target compounds synthesized, a greater antileishmanial potency against intracellular Leishmania donovani was observed as the linker length increased from two to eight carbons and when an imidazole ring was employed as the terminal group compared to a 1,2,4-triazole group. Compound 24c (N-(4-((8-(1H-imidazol-1-yl)octyl)oxy)-2-isopropoxyphenyl) picolinimidamide) displayed activity against L. donovani intracellular amastigotes with an IC50 value of 0.53 μM. When tested in a murine visceral leishmaniasis model, compound 24c at a dose of 75 mg/kg/day p.o. for five consecutive days resulted in a modest 33% decrease in liver parasitemia compared to the control group, indicating that further optimization of these molecules is needed. While potent hybrid compounds bearing an imidazole terminal group were also strong inhibitors of recombinant CYP51 from L. donovani, as assessed by a fluorescence-based assay, additional targets are likely to play an important role in the antileishmanial action of these compounds.
Design, synthesis, biological evaluation and molecular dynamics simulation studies of (R)-5-methylthiazolidin-4-One derivatives as megakaryocyte protein tyrosine phosphatase 2 (PTP-MEG2) inhibitors for the treatment of type 2 diabetes
Wu, Jingwei,Sun, Yingzhan,Zhou, Hui,Ma, Ying,Wang, Runling
, p. 3156 - 3165 (2019/08/26)
PTP-MEG2 plays a significant role in insulin production and is able to enhance insulin signaling and improve insulin sensitivity. So, PTP-MEG2 inhibitors are closely associated with type 2 diabetes therapy. A series of novel (R)-5-methylthiazolidin-4-one
Design potential selective inhibitors for human leukocyte common antigen-related (PTP-LAR) with fragment replace approach
Li, Hong-Lian,Li, Wei-Ya,Lu, Xin-Hua,Ma, Ying,Tang, Xue,Wang, Run-Ling,Wu, Jing-Wei,Zhang, Huan,Zheng, Zhi-Hui
, p. 5338 - 5348 (2019/12/24)
The overexpression of PTP-LAR could cause the insulin resistance, so PTP-LAR might be a promising target for treating diabetes. In this study, we applied the computer modeling methods with fragment replace approach to screen the fragment database by targeting PTP domain and site B with the aim to discover potent and selective PTP-LAR inhibitors. A series of novel 4-thiazolidone derivatives were gained. The results of their ADMET predictions indicated that these new compounds might become drug candidates. The series of these derivatives were synthesized. Subsequently, their PTP-LAR inhibitory activities were assayed. The compound7d showed highly selectivity for PTP-LAR (10.41 μM) over its close homolog PTP1B (IC50=44.40 μM), SHP2 (IC50>122.81 μM) and CDC25B (IC50>122.81 μM) and docking and molecular dynamics simulation were applied to propose the most likely binding mode of compound7d with PTP-LAR. Thus, our findings reported here may pave a way for discovering potential selective PTP-LAR inhibitors. AbbreviationsPTP-LAR Human leukocyte common antigen-relatedPTP Protein Tyrosine PhosphataseIR insulin receptorPTP1B Protein tyrosine phosphatase-1BLRP Lung resistance proteinADMET absorption, distribution, metabolism, excretion, toxicityPPB plasma protein bindingBBB blood brain barrier penetrationCYP450 cytochrome P450HIA human intestinal absorptionTLC thin-layer chromatographyUV Ultra VioletNMR nuclear magnetic resonanceTMS tetramethylsilaneMS mass spectrometryANM anisotropic network modePDB Protein Data BankDMF N,N-DimethylformamidepNPP para-nitrophenyl phosphateDTT dithiothreitolMD molecular dynamicRMSD root-mean-square deviationRMSF root-mean-square fluctuationSPC single-point chargePME Particle Mesh EwaldMM-PBSA molecular mechanics Poisson Boltzmann surface areaH bond, hydrogen bondVDW Van der Waals Communicated by Ramaswamy H. Sarma.
Discovery of Diphenoxy Derivatives with Flexible Linkers as Ligands for β-Amyloid Plaques
Jia, Jianhua,Zhang, Longfei,Song, Jia,Dai, Jiapei,Cui, Mengchao
, p. 4089 - 4100 (2020/12/13)
The highly rigid and planar scaffolds with π-conjugated systems have been widely considered to be indispensable for β-amyloid (Aβ) binding ligands. In this study, a library of diphenoxy compounds with different types of more flexible linkers as Aβ ligands were synthesized and evaluated. Most of them displayed good affinity (Ki1-42aggregates, and some ligands even showed values of Kiless than 10 nM. Structure-activity relationship analysis revealed that modification on the linkers or substituents tolerated great flexibility, which challenged the long-held belief that rigid and planar structures are exclusively favored for Aβ binding. Three ligands were labeled by iodine-125, and they exhibited good properties in vitro and in vivo, which further supported that this flexible scaffold was potential and promising for the development of Aβ imaging agents.
ANTI-FUNGAL TREATMENT
-
Paragraph 0096, (2018/03/25)
Provided are compounds, methods, and pharmaceutical compositions useful for treatment of fungal infections, e.g., aspergillosis, candidiasis, cryptococcosis, histoplasmosis, and the like. For example, the pharmaceutical composition may include a pharmaceutically acceptable carrier or excipient, and a compound represented by Ar— C(=NR1)NR2— A---X— Y— Het2 and pharmaceutically acceptable salts thereof. Ar may be an optionally substituted aryl or nitrogen- containing heteroaryl. R1 and R2 may independently be H, optionally substituted C1-C6 aikyi, or optionally substituted C3-C6 cyeloalkyi. A may be a bond or an optionally substituted linking moiety comprising 1, 2, or 3 rings. Each ring in the optionally substituted linking moiety may independently be one of: aryl, cyeloalkyi, heterocycloalkyl, and heteroaryl. X may be O, S, amide, or a bond. Y may be optionally substituted C1-C10 alkyi or optionally substituted C2-C10 alkenyl. Het2 may be an optionally substituted five-membered nitrogen-containing heteroaromatic ring comprising 1, 2, or 3 ring heteroatoms.
ANTI-PARASITIC COMPOUNDS
-
Paragraph 00121, (2018/03/25)
Provided are compounds, methods, and pharmaceutical compositions useful for treatment of parasites, e.g., Leishmania. For example, the compound may he represented by Ar—C(=NR1)NR2—A—X—Y—Het2, and pharmaceutically acceptable salts thereof. Ar may be an optionally substituted, aryl or nitrogen-containing heteroaryl. R1 and R2 may independently represent H, optionally substituted C1-C6 alkyl, or optionally substituted C3-C6 cycloalkyl. A may be a bond or an optionally substituted linking moiety comprising 1, 2, or 3 rings. Each ring in the optionally substituted linking moiety may independently be one of: aryl, cycloalkyl, heterocycloalkyl, and heteroaryl. X may be O, S, amide, or a bond. Y may be optionally substituted C1-C14 alkyl or optionally substituted C2-C14 alkenyl. Het2 may be an optionally substituted five-membered nitrogen-containing heteroaromatic ring comprising 1, 2, or 3 ring heteroatoms.
With high planarity of the naphthalene structure function diamine monomer and its synthetic method and application
-
Paragraph 0063; 0064; 0065, (2017/08/25)
The invention discloses functional diamine monomers having high planarity and containing a naphthaline structure and a synthesis method and application thereof. The novel functional diamine monomers are prepared from raw materials monomers such as dihalogenated naphthaline, naphthalic acid, naphthalenediol or naphthylenediamine through a series of chemical reactions such as substitution reaction, Suzuki reaction, amidation reaction, esterification reaction, Grignard reaction, Kumada coupling reaction. The diamine monomers containing a naphthaline structure, which have a lowest energy state 3D molecular structure and have high planarity, can be obtained. Due to planar space structure, the diamine monomers disclosed by the invention can serve as monomers used for preparing polymers with strong molecular chain interaction force, tight molecular chain packing and small free volume and the polymers can be endowed with an excellent barrier property. The synthesis method of the diamine monomers is simple in process and purification operation is easy; therefore, the synthesis method is suitable for industrial production. The diamine monomers disclosed by the invention can be used for synthesizing functional polymers such as polyamide, polyimide, polyamide-imide and polyester-imide.
1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
-
Paragraph 5560-5562, (2017/02/28)
The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) in-hibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and be-havioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, de? formations and chromosomal abnormalities.
Preparation and application of novel lyase in-vivo pH ratio fluorescent probe
-
Paragraph 0024, (2017/08/28)
The invention relates to preparation and application of a novel lyase in-vivo pH ratio fluorescent probe. The structure of the probe is as shown in the specification. The probe molecule is capable of dynamically monitoring variation of the lyase in-vivo p
